Last reviewed · How we verify
DHA-PPQ
DHA-PPQ is a fixed-dose combination of dihydroartemisinin and piperaquine that kills malaria parasites by generating reactive oxygen species and disrupting parasite metabolism.
DHA-PPQ is a fixed-dose combination of dihydroartemisinin and piperaquine that kills malaria parasites by generating reactive oxygen species and disrupting parasite metabolism. Used for Uncomplicated malaria caused by Plasmodium falciparum, Malaria caused by Plasmodium vivax and other Plasmodium species.
At a glance
| Generic name | DHA-PPQ |
|---|---|
| Also known as | Eurartesim |
| Sponsor | London School of Hygiene and Tropical Medicine |
| Drug class | Artemisinin-based combination therapy (ACT) |
| Target | Plasmodium falciparum and other malaria parasites (multiple targets including heme detoxification pathway) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Parasitology |
| Phase | Phase 3 |
Mechanism of action
Dihydroartemisinin (DHA), a semi-synthetic artemisinin derivative, rapidly reduces parasite biomass through oxidative stress mechanisms. Piperaquine, a bisquinoline, accumulates in parasite food vacuoles and inhibits heme detoxification. Together, they provide synergistic antimalarial activity with rapid parasite clearance and extended post-treatment suppression.
Approved indications
- Uncomplicated malaria caused by Plasmodium falciparum
- Malaria caused by Plasmodium vivax and other Plasmodium species
Common side effects
- Headache
- Fever
- Nausea
- Vomiting
- Diarrhea
- Abdominal pain
- QT prolongation (piperaquine-related)
Key clinical trials
- Investigating the Pharmacology of Tafenoquine in Papua New Guinean Children With Uncomplicated Malaria (PHASE4)
- The Transmission of Artemisinin Resistant Parasites Before and After Conventional Artemisinin-combination Therapy (PHASE4)
- Improving Maternal heAlth by Reducing Malaria in African HIV Women (PHASE3)
- Mass Drug Administration of Dihydroartemisinin-piperaquine + Single Low-dose Primaquine to Accelerate Toward Elimination Activities (NA)
- Malaria Therapeutic Efficacy Study, Rwanda (PHASE4)
- Compare the Effectiveness Between Existing Treatment and New Treatment (NA)
- Randomised Trial of 3 Artemisinin Combination Therapy for Malaria in Pregnancy (PHASE3)
- Evaluation of Three Artemisinin-based Combinations for the Treatment of Uncomplicated Malaria in Childreen in Burkina Faso (CHIMIO2) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DHA-PPQ CI brief — competitive landscape report
- DHA-PPQ updates RSS · CI watch RSS
- London School of Hygiene and Tropical Medicine portfolio CI